English EN
What BSE/TSE documentation should pharma buyers request for bovine gelatin?
Beyond Biopharma · Pharmaceutical Gelatin FAQ
Because bovine gelatin can carry a theoretical risk of transmissible spongiform encephalopathies (TSE, of which BSE is the most relevant), pharmaceutical buyers should request a clear TSE/BSE statement or certificate from the supplier confirming several points: the exact animal species (bovine) and that no other higher-risk ruminant tissue is present; the original country and, where relevant, approved-country of origin and processing country; the nature and confirmed safe status of the raw material source (typically hides or bone, from animals fit for human consumption); a statement that the material is derived from non-specified-risk material and is acceptable for pharmaceutical use; plus health/veterinary guarantees for the animals and traceability back to origin. Exactly which documents a given market will accept depends on the pharmacopoeia and the national regulatory position, so buyers should ask their regulatory affairs team and the supplier which specific certificates and wording are accepted for their target market.
Why TSE documentation exists for gelatin
Gelatin for human and veterinary pharmaceutical use normally comes from animal parts, and gelatins derived from ruminants such as cattle raise a theoretical risk of transmitting agents that cause transmissible spongiform encephalopathies. The relevant agencies and pharmacopoeias have therefore set out criteria for acceptably safe sourcing and processing, and buyers of bovine gelatin are expected to demonstrate, through documentation, that their material meets those criteria. This is standard excipient due diligence, not a reflection of risk in the product itself — modern controlled-source gelatin manufactured to typical process conditions is regarded as very low risk where the required controls are met.
What a TSE/BSE statement should show
A robust supplier statement or certificate addresses the sourcing behind the material, and typically covers these points:
| Point | Why it matters |
|---|---|
| Animal species | Confirms the source is cattle (bovine) and declares the absence of other ruminant tissues |
| Country of origin | Relevant because some markets require material from countries with a controlled BSE status |
| Raw-material nature | Confirms the tissue (e.g. hide or bone) comes from animals that passed veterinary inspection as fit for human consumption |
| Non-SRM / safe-status statement | Declares the material is not derived from specified risk material and is acceptable for pharmaceutical use |
| Health / veterinary guarantee | Assures the animals were from a healthy herd with the required disease-free guarantees |
| Traceability | Shows records trace material back from the batch to its origin |
The wording used by authorities (for example "no SRM", "from a country acceptable to the relevant authority", "process conditions acceptable for TSE reduction") can differ from one framework to the next, so ask your regulatory team which exact formulations your target market will accept.
Aligned and additional certificates of analysis
In tandem with the TSE statement, each lot or batch should be covered by a certificate of analysis recording the pharmacopoeia parameters — a TSE statement by itself is not enough. Buyers also commonly confirm the following in writing or on the COA:
- the animal source is stated as porcine, bovine or fish (and, for blends, the ratio and species);
- the process type (Type A or B, and the country of the process);
- microbiological and purity results.
How requirements vary by market
There is no single "universal" BSE/TSE package accepted everywhere. European, US, Japanese and other regulatory frameworks each describe acceptable sourcing and documentation in their own way, sometimes embedded in guidance for gelatin and gelatine capsules. What a file for one market needs may differ from another, and pharmacopoeia editions evolve. The responsible workflow is therefore to determine the target market's expectation first (with your regulatory affairs function or local representation), and only then to request the specific certificates and wording your supplier must provide.
Practical request list for the buyer
- Request a TSE/BSE statement covering species, source tissue, original country, safe-processing statement and the absence of SRM.
- Obtain current certificates of analysis for relevant pharmacopoeia parameters per batch.
- Seek traceability documentation from raw material to finished batch.
- Confirm with your regulatory affairs / quality team which wording and certificates your target market actually accepts before you finalise the request checklist.
For a broader view of the supplier compliance documents that surround gelatin purchases, see our GMP/DMF/CEP excipient question, and where generic food or pharma handling is involved confirm every point with your own teams and suppliers.
